CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program
![Thumbnail](/bitstream/handle/10576/14207/mab.2018.0042.pdf.jpg?sequence=3&isAllowed=y)
View/ Open
Date
2019Author
Thaventhiran T.Wong W.
Alghanem A.F.
Alhumeed N.
Aljasir M.A.
Ramsey S.
Sethu S.
Yeang H.X.A.
Chadwick A.E.
Cross M.
Webb S.D.
Djouhri L.
Ball C.
Stebbings R.
Sathish J.G.
...show more authors ...show less authors
Metadata
Show full item recordAbstract
CD28 superagonist (CD28SA), a therapeutic immunomodulatory monoclonal antibody triggered rapid and exaggerated activation of CD4+ effector memory T cells (TEMs) in humans with unwanted serious adverse effects. It is well known that distinct metabolic programs determine the fate and responses of immune cells. In this study, we show that human CD4+ TEMs stimulated with CD28SA adopt a metabolic program similar to those of tumor cells with enhanced glucose utilization, lipid biosynthesis, and proliferation in hypoxic conditions. Identification of metabolic profiles underlying hyperactive T cell activation would provide a platform to test safety of immunostimulatory antibodies.
Collections
- Center for Advanced Materials Research [1351 items ]